Address
1167 Massachusetts Avenue
Arlington, MA 02476
United States of America (the)
Phone
781 996 5252
Website
Sector
Healthcare
Industry
Biotechnology
Employees
38
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Avi Minkowitz | CEO, CFO & Director | 0 | 1988 |
| Mary Reumuth | Treasurer & Secretary | 1.01M | 1975 |
| Vincent Kosewski | Senior Vice President of Manufacturing & Supply Chain Management | 0 | 1963 |
| Carl Rennie | Executive Director of Account Management | 0 | N/A |
| Jill S. Steier | Executive Director of Investor Relations & Corporation Communications | 0 | N/A |
| Josiah Craver | Senior Vice President & Corporate Controller | 0 | N/A |
| Patrick Bedell | Executive Director of Trade & Alternate Channels | 0 | N/A |
| Justin Hanes | Founder & Chair of the Scientific Advisory Board | 0 | N/A |
| Francis S. Mah | Chief Medical Advisor | 0 | N/A |
Kala Bio, Inc. operates as a biopharmaceutical enterprise focused on developing and bringing to market innovative treatments. The company employs its unique, proprietary nanoparticle technology, designed to effectively penetrate mucus barriers. Initially, its efforts are concentrated on addressing various ocular conditions. Established in 2009 by founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, the firm maintains its headquarters in Arlington, Massachusetts.